ArticlePharmacoEconomics - open2026

Venetoclax in Combination with Obinutuzumab in Previously Untreated Fit Patients with Chronic Lymphocytic Leukemia: A Canadian Cost-Utility Analysis.

Gijs van de Wetering et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.